BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Kereos, Inc. Appoints Michael Loberg, NitroMed, Inc. (NTMD) President And CEO, To Board Of Directors


10/19/2005 5:11:09 PM

ST. LOUIS, May 3 /PRNewswire/ -- Kereos, a biotechnology company developing targeted therapeutics and molecular imaging agents for the treatment and detection of cancer and cardiovascular disease, announced today that Michael Loberg, Ph.D., has joined the Company's Board of Directors.

Dr. Loberg is currently President and CEO of NitroMed and also serves on the Board of Directors for Advanced Magnetics. In 2003 Dr. Loberg oversaw and led NitroMed's initial public offering process. Prior to NitroMed, Dr. Loberg spent nearly 20 years with the Bristol-Myers Squibb (BMS) organization, most recently as President, BMS Oncology & Immunology. He also served there as President, BMS Primary Care division; President, BMS Northern Europe; President, BMS Specialty Pharmaceuticals; President, Squibb Diagnostics; and Vice President of R&D. Prior to BMS, Dr. Loberg served as Associate Professor in the University of Maryland Schools of Pharmacy and Medicine. He holds a BS from Trinity College and a Ph.D. in Chemistry from Washington University in St. Louis.

"I am delighted that Dr. Loberg has agreed to bring to Kereos his many years of experience in cardiovascular and oncology drug development," said Robert "Al" Beardsley, Ph.D., CEO of Kereos. "As we advance our lead cardiovascular and cancer candidates into the clinic beginning next year, his experience at NitroMed and Bristol-Myers Squibb will be invaluable to the company."

Kereos also announced that Dr. Beardsley will present Tuesday, May 4, 2004 at 11:45 a.m. central time in the Lindell Ballroom A/B during the Biotechnology Industry Organization's BIO Mid-America Venture Forum. The conference will take place May 3-5 at the Chase Park Plaza Hotel in St. Louis.

About Kereos

Kereos develops products designed to provide more effective treatment and detection of cancer and cardiovascular disease, the first of which is expected to enter clinical trials in 2005. In addition to advancing its pipeline of therapeutic and imaging candidates independently, Kereos is committed to partnering with leading pharmaceutical and imaging companies. To date, it has formed collaborations with Bristol-Myers Squibb Medical Imaging for the development and commercialization of cardiovascular disease magnetic resonance imaging (MRI) agents and with Philips Medical Systems for the development of molecular imaging systems. For more information, visit Kereos' website at http://www.kereos.com/.

Kereos

CONTACT: Virginia Amann of Atkins & Associates, +1-608-274-6046,vamann@irpr.com for Kereos



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES